For Research Use Only. Tesamorelin is intended strictly for in vitro and preclinical animal research. It is not approved for human use, is not a drug, and should never be administered to humans. This guide does not describe clinical, therapeutic, or human applications.
What Makes Tesamorelin Sourcing Demanding
A forty four amino acid peptide is substantially larger than most research peptides. The synthesis is longer, the purification is more demanding, the mass spectrometric characterization is more complex, and the range of possible impurities is wider. Each of these factors raises the analytical and manufacturing bar for a research grade supplier. A supplier that handles smaller peptides well may not necessarily handle a peptide of this size with the same reliability, so the evaluation for tesamorelin should be specific rather than a general extension of peptide supplier assessment.
The chemistry of tesamorelin includes an N terminal trans-3-hexenoic acid modification that differentiates it from the native GHRH sequence. This modification is part of what stabilizes the peptide against enzymatic degradation and is covered in detail in the CJC-1295 / Ipamorelin Blend: What Researchers Need to Know in this cluster. The certificate of analysis for a research grade tesamorelin lot should confirm the presence and the correct attachment of this modification, not just the underlying peptide sequence.
Storage and shipping considerations for a larger peptide are also worth noting. The lyophilized powder format is standard and stable, but the reconstituted peptide requires appropriate handling for research applications. The broader peptide bioanalysis context is discussed in the umbrella bioanalysis article, which covers the analytical methods used to characterize larger peptides.
The Sourcing Criteria for Research Grade Tesamorelin
The general research peptide sourcing criteria covered in the master sourcing guide all apply to tesamorelin, with several features worth emphasizing specifically.
Third party certificate of analysis. Every lot should be characterized by an independent analytical laboratory, with the full peptide sequence confirmed by mass spectrometry and the purity documented by HPLC. The certificate should also confirm the N terminal modification that distinguishes tesamorelin from native GHRH.
Defined purity specification. Research grade tesamorelin from Midwest Peptide is supplied at a minimum of ninety five percent purity by HPLC. For a peptide of this length, maintaining this purity specification is a meaningful technical achievement that reflects the quality of the synthesis and purification process.
Mass confirmation of the modified peptide. The observed mass by mass spectrometry should match the theoretical mass for the N terminal modified peptide, not the unmodified peptide. This confirmation is part of the identity verification that a research buyer should see on the certificate.
Lot traceability. The lot number should trace back to the specific production batch, enabling reproducibility across research protocols and any quality follow up that might be needed.
Formulation. Tesamorelin is supplied as a lyophilized powder in research appropriate vial formats. The standard catalog unit is Tesamorelin 10mg per vial.
Blend availability. For research contexts that use tesamorelin in combination with ipamorelin, the Tesa/Ipa 10mg Blend is available as a combined research product that follows the ratios used in the published research literature.
Research use only compliance. The supplier should label every product strictly for research use only, without health claims or implied human use. The research applications of tesamorelin are well documented in the published literature, including the Tesamorelin Metabolic Syndrome Research: Multi-Endpoint Data, the Tesamorelin Visceral Adipose Tissue Research: Published Clinical Studies, the lipolysis research, and the lipodystrophy research covered in this cluster.
Red Flags When Evaluating Tesamorelin Suppliers
Several warning signs should remove a tesamorelin supplier from consideration.
No confirmation of the N terminal modification. A supplier whose certificate does not explicitly confirm the N terminal modification is providing incomplete analytical documentation for the peptide. The modification is part of the identity of tesamorelin, and the certificate should reflect that.
Purity specification below research grade. A supplier offering tesamorelin at purity values substantially below ninety five percent is either unable to achieve the synthesis quality that the research community expects or is attempting to pass off lower grade material.
Internal certificate without third party verification. Self certified analytical results provide weaker documentation than third party certificates. Midwest Peptide uses third party analytical laboratories specifically to provide the independent verification that research buyers should expect.
Health claims or implied human use. Any supplier that describes tesamorelin as therapeutic or implies human dosing is operating outside the research use only framework. The peptide has defined clinical research history in HIV associated lipodystrophy, which is documented in the research literature, but research grade supply is for preclinical research only.
Inconsistent lot documentation. If the lot number on the vial does not match the lot number on the certificate of analysis, or if the certificate appears to be generic rather than lot specific, the documentation is not research grade.
Opaque supplier identity. A legitimate research peptide supplier operates from a known physical location with a real customer support channel. Midwest Peptide operates from Mission, Kansas with the research support line at 636-734-2390.
What Tesamorelin Is Studied For in Preclinical Research
The Tesamorelin/Ipamorelin Blend in Research: Combining GHRH and GHRP Mechanisms covers the complete literature. The short summary is as follows.
Tesamorelin is a GHRH analog that stimulates endogenous growth hormone pulsatile release through the hypothalamic GHRH receptor pathway. The downstream research endpoints include growth hormone pulse profiles, IGF-1 axis activation, visceral adipose tissue response, lipolysis in visceral adipose depots, and body composition changes over time. The research applications span rodent models of obesity and metabolic syndrome, models of HIV associated lipodystrophy, and comparative pharmacology with other GHRH analogs such as CJC-1295 covered in the Tesamorelin GHRH Analog Chemistry: What Makes Tesamorelin Stable in Research.
The combination with ipamorelin expands the research applications by adding a ghrelin receptor agonist to the GHRH analog, producing synergistic effects on growth hormone release that have been documented in the Ipamorelin Research: Selective GHRP and Ghrelin Receptor Binding Studies in the CJC/Ipa cluster.
Frequently Asked Sourcing Questions
What is the catalog size for tesamorelin? The standard unit is Tesamorelin 10mg per vial, lyophilized powder format.
What is the purity specification? Research grade tesamorelin from Midwest Peptide is supplied at a minimum of ninety five percent HPLC purity. The lot specific value is on the third party certificate of analysis.
Is the N terminal modification confirmed on the certificate? Yes. The mass spectrometric characterization on the third party certificate of analysis confirms the full modified peptide mass, not just the peptide sequence.
Is a tesamorelin plus ipamorelin blend available? Yes. The Tesa/Ipa 10mg Blend provides the combination in a single research product.
What is the shipping timeline? Domestic shipping from Mission, Kansas through ShipStation and UPS typically reaches continental United States locations within two to four business days with tracking.
What payment methods are accepted? Zelle (five percent discount), CashApp, Venmo, Azeban Pay for credit and debit cards, and Coinbase Commerce for cryptocurrency.
Can I request additional documentation? Yes. Research laboratories needing additional analytical documentation beyond the standard certificate can contact research support at 636-734-2390.